Carfilzomib: A cause of drug associated thrombotic microangiopathy

被引：28

作者：

Qaqish, Ibrahim ^{[1
]}

Schlam, Ilana M. ^{[2
]}

Chakkera, Harini A. ^{[1
]}

Fonseca, Rafael ^{[2
]}

Adamski, Jill ^{[3
]}

机构：

[1] Mayo Clin Arizona, Dept Nephrol, 5777 East Mayo Blvd, Phoenix, AZ 85054 USA

[2] Mayo Clin Arizona, Dept Internal Med, 5777 East Mayo Blvd, Phoenix, AZ 85054 USA

[3] Mayo Clin Arizona, Dept Lab Med & Pathol, 5777 East Mayo Blvd, Phoenix, AZ 85054 USA

来源：

TRANSFUSION AND APHERESIS SCIENCE | 2016年 / 54卷 / 03期

关键词：

Thrombotic microangiopathy; Therapeutic plasma exchange; Apheresis; BORTEZOMIB; PATIENT; EXPERIENCE;

D O I：

10.1016/j.transci.2016.03.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Carfilzomib is a selective proteosome inhibitor approved for treatment of relapsed and refractory multiple myeloma. Recent reports have linked exposure to carfilzomib with development of thrombotic microangiopathy (TMA). We describe two cases of biopsy proven thrombotic microangiopathy that occurred after the initiation of carfilzomib (dosed at 32 mg/m(2) and 23 mg/m(2), respectively) for relapsed multiple myeloma. Both patients were managed with discontinuation of the drug, therapeutic plasma exchange (TPE) and supportive care. Hemoglobin, platelets and renal function did not improve with TPE. TMA resolved with creatinine returning to baseline several weeks after discontinuation of the drug. The outcomes suggest that TPE is not beneficial for treating carfilzomib-induced TMA. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：401 / 404

页数：4

共 21 条

[1] Drug-induced thrombotic microangiopathy: a systematic review of published reports [J].

Al-Nouri, Zayd L. ;

Reese, Jessica A. ;

Terrell, Deirdra R. ;

Vesely, Sara K. ;

George, James N. .

BLOOD, 2015, 125 (04) :616-618

[2]

[Anonymous], 2015, VWF MULTIMER ASSAY

[3] Thrombotic microangiopathy and associated renal disorders [J].

Barbour, Thomas ;

Johnson, Sally ;

Cohney, Solomon ;

Hughes, Peter .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (07) :2673-2685

[4] Quinine-dependent, platelet-reactive monoclonals mimic antibodies found in patients with quinine-induced immune thrombocytopenia [J].

Bougie, Daniel W. ;

Birenbaum, Jessica ;

Rasmussen, Mark ;

Poncz, Mortimer ;

Aster, Richard H. .

BLOOD, 2009, 113 (05) :1105-1111

[5] Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma [J].

Chan, Kah-Lok ;

Filshie, Robin ;

Nandurkar, Harshal ;

Quach, Hang .

LEUKEMIA & LYMPHOMA, 2015, 56 (07) :2185-2186

[6] VEGF inhibition and renal thrombotic microangiopathy [J].

Eremina, Vera ;

Jefferson, J. Ashley ;

Kowalewska, Jolanta ;

Hochster, Howard ;

Haas, Mark ;

Weisstuch, Joseph ;

Richardson, Catherine ;

Kopp, Jeffrey B. ;

Kabir, M. Golam ;

Backx, Peter H. ;

Gerber, Hans-Peter ;

Ferrara, Napoleone ;

Barisoni, Laura ;

Alpers, Charles E. ;

Quaggin, Susan E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1129-1136

[7] Evaluation of Patients with Microangiopathic Hemolytic Anemia and Thrombocytopenia [J].

George, James N. ;

Charania, Roseleen S. .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2013, 39 (02) :153-160

[8] Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma [J].

Hobeika, Liliane ;

Self, Sally E. ;

Velez, Juan Carlos Q. .

BMC NEPHROLOGY, 2014, 15

[9] Carfilzomib [J].

Kortuem, K. Martin ;

Stewart, A. Keith .

BLOOD, 2013, 121 (06) :893-897

[10] Drug-Associated Thrombotic Microangiopathies [J].

Kreuter, Justin ;

Winters, Jeffrey L. .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2012, 38 (08) :839-844

← 1 2 3 →